Biotech Startups

NeuExcell Therapeutics is a clinical-stage gene therapy company developing treatments for neurodegenerative and neurological diseases such as glioma, Alzheimer's disease, and stroke. Its ATN (Astrocytes To Neurons) platform converts glial cells into functional neurons in vivo to repair damaged brain tissue.

1 investor

Neukio is a biopharmaceutical company developing iPSC-derived cell technology platforms and next-generation off-the-shelf, mass-producible immune cell products (such as NK cells) to treat solid tumors and autoimmune diseases. It focuses on innovation in both product and process development to lower cell therapy production costs and expand indication coverage.

1 investor

Neumarker develops machine learning and biophysical tools to advance neuropsychiatric drug development and clinical care for CNS disorders. The company serves pharmaceutical and clinical organizations working on psychiatric and neurological treatments.

1 investor

Neumentum is a specialty pharmaceutical company developing non-opioid analgesic and neurology products for pain management. It has four novel non-opioid products in development aimed at treating pain while avoiding the abuse, misuse, and respiratory side effects associated with opioids.

1 investor

Neural Dynamics Technologies develops neural interface technology aimed at advancing neuroscience research and treating neurological diseases. The company brings together neuroscientists, engineers, and clinicians in an interdisciplinary approach.

1 investor

NeuralTeks develops AI-powered tools for laboratory analysis, specifically targeting microbiology and microbial identification in pharmaceutical, biotechnology, and analytical settings. The platform aims to accelerate analysis speed, improve accuracy, and reduce costs for laboratory operations.

1 investor

Neuraly is a clinical-stage biotechnology company developing disease-modifying treatments for neurodegenerative disorders, focusing on inhibiting pathological glial activation to prevent neuronal cell death. Its lead candidate NLY01 has been evaluated in Phase 2 trials for early Parkinson's disease.

1 investor

Developing a novel treatment for acute muscle spasms.

1 investor

Neurescue develops a medical device that treats cardiac arrest patients by inserting a balloon-occlusion device through the femoral artery to increase blood flow to the heart and brain during chest compressions. The device targets patients ineligible for defibrillation and uses automated pressure-limited inflation to improve resuscitation outcomes.

1 investor

Neurochase provides consultancy to biotech and pharmaceutical companies on directly delivering therapies to the central nervous system, drawing on experience with catheter infusions and convection-enhanced delivery. It supports preclinical study protocols, toxicology, surgical workflow and training, and is developing its own CED drug-delivery devices.

1 investor

NeuroDex develops blood-based biomarkers and diagnostic assays for neurological diseases, including rare genetic disorders, Parkinson's disease, Alzheimer's disease, and ALS. The company works with biopharmaceutical companies to enable patient selection, treatment monitoring, and accelerated disease diagnosis in clinical development programs.

1 investor

1 investor

Neurogene develops gene therapy treatments for rare neurological diseases. The company aims to make severe genetic neurological conditions treatable for patients and families impacted by these conditions.

1 investor

NeuroGevity develops a sleep headband with biometric sensors and AI algorithms to assess brain health and detect neurophysiological biomarkers at home. The company also offers sound-based stimulation synchronized to brain activity to enhance slow-wave sleep and memory consolidation.

1 investor

NeuroGenesis develops cell therapies for neurodegenerative diseases, leveraging its NG CELL platform to enhance stem cells for treating conditions like multiple sclerosis and ALS. The company is advancing Phase IIb clinical trials in Europe and Israel with a focus on remyelinating and regenerative cellular medicine.

1 investor

NeuroKaire uses cellular modeling and biological measurement to help mental health providers and patients make treatment decisions for depression based on measurable biological response rather than trial-and-error approaches. The company offers diagnostic testing through CLIA-certified laboratories to provide earlier biological context for antidepressant selection.

1 investor

Neurolieve is a life-science company developing therapeutics for neuropathic and chronic pain, with expertise in neuroscience, clinical pain medicine and drug development. Its lead program, NLV-01, is built on protein-engineering technology contributed by co-founding partner LifeArc.

1 investor

Neuromorphic develops hardware-agnostic control software for robots, letting operators deploy and manage them through everyday interfaces such as Slack, email, and phone. It targets wet labs and other physical industries that want to add robots with minimal setup.

1 investor

Neuronity develops therapies that enhance immune cell activity in the aging brain to prevent neurodegenerative disease progression. The company targets patients with age-related neurological conditions.

1 investor

Neurophyxia is developing a neuroprotectant compound (2-iminobiotin) for treating brain injury and tissue damage caused by stroke, cardiac arrest, and birth asphyxia. The compound is in Phase IIb/III clinical development.

1 investor

NeuroSky provides biofeedback and biometric assessment solutions that help companies optimize hiring decisions, identify employee training needs, and improve workforce productivity through data-driven insights on cognitive performance and employee capabilities.

1 investor

Axoneurotech develops neural engineering technology using a biology-first approach at the intersection of biology and engineering.

1 investor

Neuroute is an AI-powered platform that accelerates clinical trial execution through patient recruitment, trial monitoring, and predictive analytics. It serves pharmaceutical companies and clinical research organizations conducting clinical trials.

1 investor

1 investor